• Thanks For Visiting
    Thanks For Visiting
  • Featured Guest Post
    Featured Guest Post
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

Special News Reports

Tue04242018

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018

Detailed Characterization of Unique DolaLock Technology Enhancements to Drug Efficacy and Tolerability
XMT-1522 Demonstrates Synergy in Combination with a Checkpoint InhibitorCAMBRIDGE, Mass., April 17, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin and other proprietary platforms, today announced new data on Mersana’s lead ADC platform, Dolaflexin, and on the HER2 targeted ADC XMT-1522, presented as part of the 2018 American Association for Cancer Research (AACR) Annual Meeting bei...


Posted: 2018-04-17 17:01:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.






Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018 | Globe NewsWire News Distribution Service - Newscast

Resy Demonstrates Strategic Growth & Reveals First-of-its-Kind Hospitality Tools to Empower Restaurants on a Global Scale

Tue, 17 Apr 2018 10:41:00 GMT

NEW YORK, April 17, 2018 (GLOBE NEWSWIRE) — Today, hospitality technology leader Resy revealed a disruptive ... customize private post-meal surveys to gain insight into all aspects of their operation — from steps of service, to customer behavior ...

Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018

Tue, 17 Apr 2018 10:22:00 GMT

CAMBRIDGE, Mass., April 17, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin and other ...

Sareum : AACR 2018 Update

Mon, 16 Apr 2018 17:00:00 GMT

Sareum Notes that Sierra Oncology will Present Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARP Inhibitors at the AACR 2018 Annual Meeting Two ... The Company's drug discovery technology platform (SKIL® - Sareum Kinase Inhibitor ...

Just How Smart Is Smart Medicine? MIT Scientists Are About To Find Out

Tue, 10 Apr 2018 14:18:00 GMT

A microbial geneticist by training, Miller is accountable for all aspects of discovery research and platform expansion at the ... American Association for Cancer Research (AACR) being held April 14 to 16, 2018, in Chicago. The presentations will cover ...

Cellectar Biosciences' (CLRB) CEO James Caruso on Q4 2017 Results - Earnings Call Transcript

Thu, 22 Mar 2018 11:12:00 GMT

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2017 Earnings Conference Call March 22, 2018 8:30 AM ET Executives Anne Marie ... in brain tumors underscored the potential of our PDC platform technology to selectively deliver oncologic payloads to highly ...

Related Bing Web Search

MRSN Stock Price - Mersana Therapeutics Inc. Stock Quote ...

(Sun, 22 Apr 2018 16:50:00 GMT)

Mersana Therapeutics Inc. stock price, stock quotes and financial overviews from MarketWatch.

DROPBOX, INC. (DBX) IPO - NASDAQ.com

(Sun, 22 Apr 2018 20:03:00 GMT)

Latest News Headlines. Akcea Therapeutics to Present Data on Inotersen for the Treatment of hATTR Amyloidosis at the 2018 12:38PM ET - GlobeNewswire

Rgenix | Innovative cancer drugs to benefit humanity

(Sun, 22 Apr 2018 20:32:00 GMT)

Rgenix is a clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Rgenix's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression.

CheapBooks - Buy Books, Book News and Reviews

(Fri, 20 Apr 2018 12:20:00 GMT)

Intelex Announces EHSQ Alliance Award Winners Top Customers Honored at the 2018 EHSQ Alliance Conference Changing Business for Good AUSTIN TX April 18 2018 PRNewswire - Winners of the 2018 EHSQ Alliance Awards were announced today recognizing innovation leadership commitment and outstanding achieve

BioTek Instruments

(Thu, 19 Apr 2018 21:18:00 GMT)

Agilent and BioTek Join Forces to Create an Integrated Metabolic Analysis and Imaging Platform April 4, 2018 - SANTA CLARA CA, WINOOSKI VT, USA — Agilent Technologies Inc. (NYSE: A) and BioTek Instruments, Inc., today announced a collaboration to develop a new, integrated solution that combines cellular metabolic analysis and imaging ...

Speakers | Australian Lung Cancer Conference

(Wed, 18 Apr 2018 06:25:00 GMT)

Justin Gainor, MD, a thoracic oncologist at the Mass General Cancer Center, conducts intensive research on developing novel targeted therapies for patients with genetically-defined forms of lung cancer and designs clinical trials to evaluate these complex, life-saving treatments.

Fluidigm

(Sun, 22 Apr 2018 05:37:00 GMT)

Fluidigm creates and manufactures innovative technologies and life-science tools designed to revolutionize biology through ongoing pursuit of scientific truth.

Vividion Therapeutics: Creating a New Era in Drug Discovery

(Sat, 21 Apr 2018 22:35:00 GMT)

Vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide drug and target discovery.

Pharma Congress 2018 - Pharmaceutical Conferences 2018 ...

(Sun, 22 Apr 2018 22:19:00 GMT)

Meet leading experts in the field of Pharma, Pharmacy, pharmaceutical industry, and Pharmaceutical Business Development at world pharma congress, pharma conferences

GRAIL | Combining Science, Tech and Clinical Studies to ...

(Sun, 22 Apr 2018 23:38:00 GMT)

GRAIL is taking on one of the biggest challenges of our lifetime, combining science, technology, and clinical studies to reveal cancer at its beginnings.

Related News Story Videos From Youtube

TRACO 2017 - Clinical trials and Precision Medicine


Related Videos On: TRACO 2017 - Clinical trials and Precision Medicine


Translating the cancer genome: transforming cancer care


Related Videos On: Translating the cancer genome: transforming cancer care






Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
Copyright; 2008-2018 RobinsPost (The Bird's Eye View Company) All rights reserved.
News stories from trusted sources. RobinsPost.com provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by respective news sources.
ROBINSPOST.COM Is Proudly Made In America. - Where Quality, Safety and Service Comes First.